Innovative Research Award

Olawunmi Oyedeji
The Christie NHS Foundation Trust

Olawunmi Oyedeji
Affiliation	The Christie NHS Foundation Trust
Country	United Kingdom
Scopus ID	58803277000
Documents	2
Citations	2
h-index	2
Subject Area	Oncology
Event	Global Diseases Research Awards
ORCID	0009-0008-0626-3422

Olawunmi Oyedeji is a researcher affiliated with The Christie NHS Foundation Trust, United Kingdom, whose academic activities contribute to the field of oncology research. The Innovative Research Award recognizes researchers demonstrating valuable contributions through scientific investigation, clinical advancement, and knowledge development within their respective disciplines. [1]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

The Innovative Research Award highlights academic excellence and meaningful contributions in oncology research. Olawunmi Oyedeji, affiliated with The Christie NHS Foundation Trust, United Kingdom, represents emerging research activities focused on advancing healthcare knowledge and improving scientific understanding. With documented publications, citations, and research engagement indexed through Scopus, the researcher demonstrates participation in scholarly communication. The award recognizes dedication toward innovative approaches, evidence-based practices, and contributions supporting progress in global disease research and clinical advancement. [1]

Keywords

Oncology Research, Clinical Research, Innovative Research Award, Cancer Research, Healthcare Innovation

Introduction

Oncology research plays an important role in understanding cancer biology, improving diagnosis, and developing effective therapeutic strategies. Researchers working within clinical and academic institutions contribute essential evidence that supports improvements in patient care and healthcare systems. [2]

Research Profile

Olawunmi Oyedeji is associated with The Christie NHS Foundation Trust, a leading healthcare institution in the United Kingdom. The research profile includes two indexed documents, two citations, and an h-index of two according to available Scopus information. [1]

Research Contributions

The researcher’s contributions are positioned within oncology and healthcare research. Scientific contributions in this area support better understanding of diseases, treatment approaches, clinical methodologies, and evidence-based medical practices. Such efforts strengthen collaborative research environments and promote advancement in cancer-related knowledge. [2]

Publications

The researcher has published scholarly documents indexed within Scopus databases. These publications contribute to academic discussions in oncology and related healthcare disciplines. Research outputs provide opportunities for knowledge exchange and future scientific collaboration among international researchers. [3]

Research Impact

Research impact is reflected through scholarly visibility, citation activity, and contribution to scientific literature. The available metrics indicate participation in academic research communication and demonstrate the importance of continued investigation within oncology and clinical sciences. [4]

Award Suitability

The Innovative Research Award recognizes researchers who demonstrate commitment toward scientific advancement and meaningful research activities. Based on the researcher’s oncology-focused profile, institutional affiliation, and academic contributions, Olawunmi Oyedeji represents a suitable candidate for recognition within the Global Diseases Research Awards framework. [4]

Conclusion

Olawunmi Oyedeji’s research profile demonstrates involvement in oncology-related scientific activities through institutional association, publications, and academic indexing. The Innovative Research Award acknowledges continued efforts toward research development and contributions supporting healthcare innovation and global scientific progress.

External Links

References

Elsevier. (n.d.). Scopus author details: Olawunmi Oyedeji, Author ID 58803277000. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=58803277000
Global Diseases Research Awards. (n.d.). Innovative Research Award Information.
https://globaldiseases.org/
Oisakede, E. O., Oyedeji, O. O., Olawuyi, O. F., Alabi, J. O., Daniel, R. I. A., & Olawade, D. B. (2026). Nanoparticle-mediated cardiotoxicity and nanomedicine interventions in cancer treatment. Nano TransMed, 5, Article 100113.
https://doi.org/10.1016/j.ntm.2026.100113
Oyedeji, O. O., & Oisakede, E. O. (2026). Radiation-induced rhinosinusitis after treatment of nasopharyngeal and selected sinonasal cancers: A narrative review. Sinusitis, 10(1), Article 100015.
https://doi.org/10.3390/sinusitis10010015

Dr. Ashok Kumar Pandurangan | Cancer Drug | Distinguished Scientist Award

Associate Professor | B.S. Abdur Rahman Crescent Institute of Science and Technology | India

Dr. Ashok Kumar Pandurangan, Ph.D., is an accomplished Associate Professor at the School of Life Sciences, B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, India. His extensive research focuses on signal transduction in colon and breast cancer, ulcerative colitis and colitis-associated cancer, and natural product-based drug development and screening. With over a decade of international research experience, including postdoctoral fellowships at the University of Malaya, Universiti Putra Malaysia, and Children’s Hospital Oakland Research Institute (UCSF Benioff), Dr. Pandurangan has made significant contributions to cancer biology and therapeutic research. He has successfully led and collaborated on numerous national and international grants, advancing translational cancer studies. His exceptional academic record includes being listed among the Top 2% Scientists worldwide (2021–2024) by Stanford University, and he has received several prestigious awards such as the AGAR Research Excellence Award (2025) and the C.V. Raman Prize (2022) for outstanding research achievements. Dr. Pandurangan also serves as an Associate Editor for Frontiers in Cellular and Infection Microbiology and has edited multiple special issues and scientific books. His prolific scholarly output includes 100 publications, covering high-impact ISI and Scopus-indexed journals, 2,714 citations, and an h-index of 30, reflecting his substantial influence and enduring contributions to the fields of oncology, toxicology, and biomedical research

Featured Publications

1. Pandurangan, A. K. (2013). Potential targets for prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt pathways. Asian Pacific Journal of Cancer Prevention, 14(4), 2201–2205. Cited by 239

2. Ashokkumar, P., & Sudhandiran, G. (2008). Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomedicine & Pharmacotherapy, 62(9), 590–597. Cited by 203

3. Ashok Kumar Pandurangan, Z. S., Mohebali, N., Mohd Esa, N., Chung, … (2015). Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: Possible mechanisms. International Immunopharmacology, 28(2), 1034–1043. Cited by 192

4. Ashok Kumar Pandurangan, N. M. E. (2014). Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: A review. Asian Pacific Journal of Cancer Prevention, 15(14), 5501–5508. Cited by 168

5. Degagné, E., Pandurangan, A., Bandhuvula, P., Kumar, A., Eltanawy, A., … (2014). Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. The Journal of Clinical Investigation, 124(12), 5368–5384. Cited by 164

Olawunmi Oyedeji | Oncology | Innovative Research Award